Advances in treatment of de-novo pediatric acute myeloid leukemia

Area of Science:

• Hematology
• Pediatric Oncology
• Molecular Biology

Background:

• Pediatric acute myeloid leukemia (AML) survival has improved significantly over 40 years, yet progress has plateaued.
• Childhood AML presents diverse subtypes with varied prognoses, with approximately 35% of patients succumbing to the disease.
• Survivors of pediatric AML often experience debilitating long-term effects, highlighting the need for optimized treatment strategies.

Purpose of the Study:

• To outline current management approaches for de-novo pediatric acute myeloid leukemia (AML).
• To discuss the distinct biology of pediatric AML compared to adult forms.
• To exclude specific subtypes like promyelocytic leukemia and myeloid neoplasms in trisomy 21.

Main Methods:

• Review of clinical trials published within the last five years.
• Analysis of therapeutic concepts and their impact on disease-free survival.
• Evaluation of strategies for managing central nervous system leukemia and supportive care quality.

Main Results:

• Intensive initial myelosuppressive chemotherapy is crucial for reducing minimal residual disease and improving survival.
• Post-remission chemotherapy, potentially with hematopoietic stem cell transplantation, is essential for AML eradication.
• Intrathecal chemotherapy effectively manages central nervous system leukemia, with radiotherapy rarely needed. Survival differences are linked to patient selection and supportive care.

Conclusions:

• Further progress in pediatric AML necessitates a deeper understanding of its underlying biology.
• Development and introduction of novel agents targeting specific AML subtypes and age-related factors are critical.
• Optimizing treatment strategies requires addressing both disease-specific and patient-specific elements.